SLC5A2 and heart failure: According to Aziri et al. [76] (12 studies, n=83878), SGLT-2 inhibitors improved the quality of life in heart failure individuals (atrial fibrillation (OR=0.83, 95% CI: 0.68-1.01), HHF (OR=0.69, 95% CI: 0.60-0.78), cardiovascular death (OR=0.82, 95% CI: 0.58-1.15), and MACE (OR=0.90, 95% CI: 0.77-1.06)).